LATEST TRENDS IN THE OR

ASPEN Philippines Inc.

About Aspen

Aspen is a leading global player in specialty and generic pharmaceuticals with an extensive basket
of products that provide treatment for a broad spectrum of acute and chronic conditions
experienced through all stages of life. Aspen continues to increase the number of lives benefitting
from its products, reaching more than 150 countries.

Aspen has a strong presence in both emerging and developed countries. Its emerging market
footprint includes Sub-Saharan Africa (where it is the largest pharmaceutical company), Latin
America, South East Asia, Eastern Europe and the Commonwealth of Independent States,
comprising Russia and the former Soviet Republics. From a developed world perspective Aspen is
one of the leading pharmaceutical companies in Australia and has a growing presence in other
developed countries, most notably in Western Europe.

Aspen operates with an established business presence in approximately 50 countries spanning 6

continents and employs more than 10,000 people. The Group operates 26 manufacturing facilities
across 18 sites. Aspen holds international manufacturing approvals from some of the most
stringent global regulatory agencies including the FDA, TGA and EMA. Aspen’s manufacturing
capabilities are scalable to demand and cover a wide variety of product-types including oral solid
dose, liquids, semi-solids, steriles, biologicals, APIs and INs.

Aspen, with a market capitalisation of approximately $10 billion, is the largest pharmaceutical
company listed on the JSE Limited (share code: APN) and ranks amongst the top 20 listed
companies on this exchange.

Anaesthetic products are categorised into two classes, namely general

anaesthetics, which cause a reversible loss of consciousness; and local or regional
anaesthetics, which cause a reversible loss of sensation locally (eg for local
surgical procedures) or for a limited region of the body such as epidural
anaesthesia, while maintaining consciousness.
Aspen’s acquisition of the rights to six local or regional and one general AstraZeneca anaesthetic products
globally (except the USA), and five GSK anaesthetic products for general anaesthesia use globally (with the
exception of certain territories, primarily North America) will position it as one of the leading providers of
anaesthetic products worldwide as it will hold a 20% share in this therapeutic category globally (outside
the USA), a sector IMS values at USD3 billion, and will be the leading supplier of these products in multiple
countries, including China, Japan, Brazil, South Africa, Australia and certain Nordic countries. As a
consequence of these transactions four of the top 10 anaesthetic products globally (excluding the USA)
will be Aspen products.

A variety of products is used in general anaesthesia for induction, maintenance and recovery. The classes
of products where Aspen has acquired the rights in general anaesthesia are related to:

 induction and maintenance (Diprivan – acquired from AstraZeneca);

 opioids used during induction, maintenance and recovery (Ultiva – acquired from GSK); and
 neuro-muscular, blocking drugs used to facilitate intubation and to relax the muscles for surgical
procedures (Nimbex, Tracrium, Mivacron and Anectine – acquired from GSK).
Local/regional anaesthetics include topical agents, in which class Aspen has acquired ointments, creams,
gels, patches and sprays (Emla – acquired from AstraZeneca)

A key element of our growth strategy is to identify therapeutic areas that are specialised in nature and a
good -t with existing operations. In line with this strategy, we acquired the AstraZeneca and the GSK
anaesthetics portfolios in 2017 which presented an opportunity to leverage both our existing sterile
manufacturing capabilities and our hospital focused sales force. In November 2017, we acquired the
remaining rights to the intellectual property and manufacturing know-how related to the AstraZeneca
portfolio. We believe that increased control over the supply chain will enhance our ability to achieve
manufacturing synergies and thus support earnings growth. Our diverse product range includes general
anaesthetics, muscle relaxants as well as a number of local anaesthetics including topical agents.

Diprivan  (propofol)  Short-acting intravenous sedative

  / anaesthetic

EMLA  (lidocaine + prilocaine)  Topical anaesthetic

Naropin  (ropivacaine  Local anaesthesia solution for

injection

Xylocaine  (lidocaine / lignocaine)  Local anaesthesia solution for

injection
 Solutions also available with
added adrenaline
(vasoconstrictor) in some
countries/presentations
 Also available in several
additional forms for topical pain
relief
 Injectable antiarrhythmic

AstraZeneca’s anaesthetics portfolio comprises seven established medicines, namely Diprivan

(general anaesthesia), EMLA (topical anaesthetic) and five local anaesthetics
(Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest) (“the Portfolio”). The
products in the Portfolio are sold in more than one hundred countries worldwide including China,
Japan, Australia and Brazil. These products generated revenue of US$ 592 million in the year ended
31 December 2015.

About AstraZeneca’s anaesthetics portfolio

 Carbocaine (mepivacaine) Local Anaesthesia solution for injection for the following

techniques: local infiltration, minor and major nerve blocks, epidural block and arthroscopy.

 Citanest (prilocaine) Local Anaesthesia solution for injection for the following techniques:
local infiltration, minor and major nerve blocks, Epidural block, arthroscopy and intravenous
regional anaesthesia.

 Diprivan (propofol)  Short acting intravenous sedative / anaesthetic for the following:
induction / maintenance of general anaesthesia, sedation of ventilated ICU patients and
conscious sedation for surgical / diagnostic procedures.

 EMLA (lidocaine + prilocaine)  Topical Anaesthetic 1g Cream/single patch contains a eutectic

mix of 25mg of each of two local anaesthetics (lidocaine & prilocaine), for the following:

Cream Anaesthesia of skin for needle insertion, superficial surgical procedures, genital mucosa (eg,
prior to superficial surgical procedures or infiltration), leg ulcers, to facilitate mechanical
cleansing/debridement

Patch Anaesthesia of intact skin in connection with minor procedures, such as needle insertion and
surgical treatment of localized lesions

 Marcaine (bupivacaine)  Local Anaesthesia solution for injection for the following: local
anaesthesia including infiltration, minor and major nerve blocks, epidural block and
arthroscopy.

 Naropin (ropivacaine)  Local anaesthesia solution for injection for the following:

Surgical anaesthesia epidural block for surgery, including caesarean section, intrathecal, major nerve
block and field block

Acute pain management: continuous epidural infusion or intermittent bolus, field block, intra-
articular injection, continuous peripheral nerve block infusion or intermittent injections

Acute pain management in paediatrics for peri-and postoperative pain; caudal epidural block,
peripheral nerve block

 Xylocaine (lidocaine / lignocaine)  Local Anaesthesia solution for injection for the following:
local infiltration, minor and major nerve blocks, epidural block, arthroscopy, intravenous
regional anaesthesia and topical anaesthesia.
Aspen Xylocaine spray nozzle can be bought separately (call: 639163107761/639167074654)

https://www.aspenpharma.com/group-news/